Thrombin generation assay: A new tool to predict and optimize clinical outcome in cardiovascular patients?

Blood Coagulation and Fibrinolysis

Volumn 23, Issue 8, 2012, Pages 680-687

  Campo, Gianluca ^a,b   Pavasini, Rita ^a,b   Pollina, Alberto ^a,b   Fileti, Luca ^a,b   Marchesini, Jlenia ^a,b   Tebaldi, Matteo ^a,b   Ferrari, Roberto ^a,b,c  

^a UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^b LTTA Center   (Italy)

^c IRCCS   (Italy)

Author keywords

bivalirudin; fondaparinux; low molecular weight heparin; thrombin generation assay; unfractionated heparin

Indexed keywords

ANTICOAGULANT AGENT; DABIGATRAN; FONDAPARINUX; HEPARIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KAOLIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ANTICOAGULATION; ATHEROSCLEROTIC PLAQUE; BLEEDING TENDENCY; BLOOD CLOTTING; BLOOD EXAMINATION; CARDIOVASCULAR DISEASE; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; ENZYME SYNTHESIS; HUMAN; ISCHEMIA; LUNG EMBOLISM; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; RISK ASSESSMENT; THROMBIN GENERATION ASSAY;

ACUTE CORONARY SYNDROME; ANTITHROMBINS; BIOLOGICAL ASSAY; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; PREDICTIVE VALUE OF TESTS; THROMBIN; THROMBOSIS; TREATMENT OUTCOME;

EID: 84870242904     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328355111f     Document Type: Review

References (27)

1. Silvain J, Collet J, Nagaswami C, Beygui F, Edmondson K, Appaix AB, et al. Composition of coronary thrombus in acute myocardial infarction. J Am Coll Cardiol 2011; 57:1359-1367.
2. Hirsh J, O'Donnel M, Weitz JI. New anticoagulants. Blood 2005; 105:453-463. (Pubitemid 40070721)
3. Depasse F, Gerotziafas GT, Busson J, VanDreden P, Samama MM. Assessment of three chromogenic and one clotting assays for the measurement of synthetic pentasaccaharide fondaparinux anti-Xa activity. J Thromb Haemost 2004; 2:346-348. (Pubitemid 40186052)
4. Castoldi E, Rosing J. Thrombin generation tests. Thromb Res 2011; 127:S21-S25.
5. Chandler WL, Roshal M. Optimization of plasma flourogenic thrombingeneration assays. Am J Clin Pathol 2009; 132:169-179.
6. Tanaka KA, Szlam F, Sun HY, Taketomi T. Thrombin generation assay and viscoelastic coagulation monitors demonstrate differences in the mode of thrombin inhibition between unfractionated heparin and bivalirudin. Anesth Analg 2007; 105:933-939. (Pubitemid 47479303)
7. Samama MM, Le Flem L, Guinet C, Geroftziafas G, Depasse F . Three different patterns of calibrated automated thrombogram obtained with six different anticoagulants. J Thromb Haemost 2007; 5:2554-2556. (Pubitemid 350154370)
8. Gerotziafas GT, Petrupoulou AD, Verdy E, Samama MM, Elamy I. Effect of the antifactor Xa and antifactor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation. J Thromb Haemost 2007; 5:955-962. (Pubitemid 46691725)
9. Robert S, Ghiotto J, Pirotte B, David JL, Masereel B, Poche L, et al. Is thrombin generation the new rapid, reliable and relevant pharmacological tool for the development of anticoagulant drugs? Pharmacol Res 2009; 59:160-166.
10. Hirsh J, O'Donnell M, Eikelboom JW. Beyond unfractionated heparin and warfarin: current and future advances. Circulation 2007; 116:552-560. (Pubitemid 47450264)
11. Samama MM, Mendell J, Guinet C, Le Flem L, Kunitada S. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. Thromb Res 2012; 129:e77-e82.
12. Desmurs-Clavel H, Huchon C, Chatard B, Negrier C, Dargaud Y. Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aCCP and PCC. Thromb Res 2009; 123:796-798.
13. Bijsterveld NR, Moons AH, Boekholdt SM, E van Aken B, Fennema H, Peters RJG, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccaharide fondaparinux in healthy volunteers. Circulation 2002; 106:2550-2554. (Pubitemid 35340690)
14. Szlam F, Sreeram G, Solomon C, Levy JH, Molinaro RJ, Tanaka KA. Elevated factor VIII enhances thrombin generation in the presence of factor VIII-deficiency, factor XI-deficiency or fondaparinux. Thromb Res 2011; 127:135-140.
15. Ammollo CT, Semeraro F, Incampo F, Semeraro N, Colucci M. Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin activatable fibrinolysis inhibitor. J Thromb Haemost 2010; 8:790-798.
16. Gatt A, van Veen JJ, Bowyer A, Woolley AM, Cooper P, Kitchen S, et al. Wide variation in thrombin generation in patients with atrial fibrillation and therapeutic International Normalized Ratio is not due to inflammation. Br J Haematol 2008; 142:946-952.
17. Seljeflot I, Hurlen M, Arnesen H. Increased levels of soluble tissue factor during long-term treatment with warfarin in patients after an acute myocardial infarction. J Thromb Haemost 2004; 2:726-730. (Pubitemid 40185710)
18. MacCallum PK, Rudnicka AR, Rumley A, Meade TW, Lowe GDO. Low-intensity warfarin reduces thrombin generation and fibrin turnover, but not low-grade inflammation, in men at risk of myocardial infarction. Br J Haematol 2004; 127:448-450. (Pubitemid 39536598)
19. Cipollone F, Mezzetti A, Porreca E, Di Febbo C, Nutini M, Fazia M, et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 2002; 106:399-402. (Pubitemid 34803680)
20. Sanguigni V, Pignatelli P, Lenti L, Ferro D, Bellia A, Carnevale R, et al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 2005; 111:412-419. (Pubitemid 40204424)
21. Skeppholm M, Kallner A, Malmqvist K, Blombäck M, Wallén H. Is fibrin formation and thrombin generation increased during and after an acute coronary syndrome? Thromb Res 2011; 128:483-489.
22. Oliveiri O, Martinelli N, Girelli D, Pizzolo F, Friso S, Beltrame F, et al. Apolipoprotein C-III predicts cardiovascular mortality in severe coronary artery disease and is associated with an enhanced plasma thrombin generation. J Thromb Haemost 2010; 8:463-471.
23. Brummel-Ziedinis K, Undas A, Orfeo T, Giessel M, Butenas S, Zmudkaet K, et al. Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor composition. J Thromb Haemost 2008; 6:104-110.
24. Merlini PA, Repetto A, Lombardi A, Vetrano A, Fetiveau R, Cavallini C, et al. Effect of abciximab on prothrombin activation and thrombin generation in acute coronary syndromes without ST-segment elevation: GUSTO IV ACS Italian Hematologic substudy. Circulation 2002; 105:928-932.
25. Granger CB, Miller JM, Bovill EG, Gruber A, Tracy RP, Krucoff MW, et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995; 91:1929-1935.
26. Orfeo T, Gissel M, Butenas S, Undas A, Brummel-Ziedinsand KE, Mann KG. Anticoagulants and the propagation phase of thrombin generation. PloS ONE 2011; 6:e27852.
27. Campo G, Saia F, Guastaroba P, Marchesini J, Varani E, Manari A, et al. Prognostic impact of hospital readmissions after primary percutaneous coronary intervention. Arch Intern Med 2011; 171:1948-1949.